Kenny Walter

There was not a statistically significant difference in eGFR between kidney recipients of HCV positive and negative donors.

Amputations have increased 30% among diabetic patients since the pandemic began.

There is concern over whether or not patients are adhering to their treatment during the pandemic.

Approximately 30% of patients treated with upadacitinib achieved endoscopic mucosal improvement at week 8, compared to just 7% of the placebo group

Dr. Gerald Shulman discusses how diabetes can eventually be reversed.

More studies are needed to examine other methods of ADHD assessments.

By addressing insulin resistance, researchers believe they can reduce the comorbidities associated with type 2 diabetes.

Experts expect more individuals to face mental health challenges caused by the events of 2020.

Dr. Giorgino discusses how combining SGLT2 Inhibitors and GLP-1RA could be combined for treating type 2 diabetes.

Diabetic patients are more susceptible to severe COVID-19 outcomes.

Dr. Kausik Ray presents new data on inclisiran and bempedoic acid as cholesterol lowering medications.

Despite the difficult circumstances, experts believe colorectal cancer rates will not decrease in the coming years due to delays in screenings.

The top-line results from the ABX464 study conducted in 15 European countries, as well as the US and Canada, are expected during the second quarter of 2021.

The drug is indicated in capsule form for adults and in a liquid formulation for children.

Repeated Transcranial Magnetic Stimulation shows more efficacy treating bipolar disorder than schizophrenia.

In a poster presented at ACG, investigators find a new patch test could help patients who are not responding to PPI therapy.

The approval represents the first ever therapy for chronic weight management for obesity caused by a trio of genetic deficiencies.

Liquidia Technologies plans on addressing FDA concerns regarding treprostinil.

Dr. Tobias Moeller-Bertram discusses how alternative therapies could replace opioids in the future for chronic pain.

More studies are planned testing the impact of finerenone.

Finerenone could be another option to SGLT2 inhibitors for this patient population.

The rates of ALT normalization maintained in both arms of the 96 week study.

A week-long treatment program prevented HCV transmission in 88% of cases.

In data from several studies presented at AHA 2020, investigators tout bempedoic acid in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia.

The agency did not find any efficacy or safety issues regarding the potential treatment for adults with schizophrenia or bipolar I disorder.

There was very little difference found in visual acuity whether or not anti-VEGF treatments were used.

In data presented at AAO 2020, investigators test imaged guided intravitreal aflibercept injections for sight improvements.

Adamis plans to address agency concerns regarding the naloxone injection application.

A discrepancy regarding a pre-licensing inspection of a third-party manufacturing facility led to the Complete Response Letter.

In data presented at AAO, investigators examine the impact of anti-VEGF injections on ocular hypertension.